This paper summarizes the pharmacologic properties of vasoactive medications used in the
treatment of shock, including the inotropes and vasopressors. The clinical application of …

Why are some organizations error-prone—regularly subject to interruptions and inconveniences,
some of which periodically coalesce catastrophically—whereas other organizations, …

Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

Background Monoclonal antibody treatment may prevent complications of coronavirus
disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal …

Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-…

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
high-risk outpatients with mild to moderate COVID-19; however, only intravenous …

Background Monoclonal antibody (mAb) treatment is associated with decreased risk of
hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease 2019 …

Background Accumulating evidence from clinical trials suggests that a lower (restrictive)
hemoglobin threshold (<8 g/dL) for red blood cell (RBC) transfusion, compared with a higher (…

The purpose of this study was to compare the performance of anti-factor Xa concentration
versus activated partial thromboplastin time (aPTT) monitoring with multiple indication-specific …

Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19
specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) …